ALLO vs JNJ
ALLO: Allogene Therapeutics is pioneering off-the-shelf, donor-derived CAR T cell therapies to provide more scalable and accessible cancer and autoimmune disease treatments. JNJ: A global healthcare leader spanning pharmaceuticals, medical devices, and consumer health products, with a portfolio spanning acute care, oncology, immunology, cardiovascular, and infectious disease.
Side-by-side fundamentals
| Metric | ALLO | JNJ | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $1.86 | $255.63 | |
| Market cap as of 2026-07-23 | $637M | $614.6B | |
| P/E as of 2026-07-23 | n/a | 29.22 | |
| PEG as of 2026-07-23 | n/a | 3.16 | |
| Net margin as of 2026-07-23 | -269835.0% | +21.5% | JNJ higher |
| Gross margin as of 2026-07-23 | n/a | +68.0% | |
| Operating margin as of 2026-07-23 | -274487.8% | +25.7% | JNJ higher |
| ROE as of 2026-07-23 | -57.1% | +26.3% | JNJ higher |
| ROA as of 2026-07-23 | -41.6% | +10.7% | JNJ higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.68 | ALLO lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +8.1% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +6.2% | |
| Dividend yield as of 2026-07-23 | n/a | +2.1% | |
| Dividend streak (yrs) SEC XBRL | 0 | 5 | JNJ higher |
| Beta as of 2026-07-23 | 0.46 | 0.23 | |
| 1-year return as of 2026-07-22 close | +40.2% | +52.2% | JNJ higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.